Guidance for the development of evidence-based vaccine-related recomhttp://apps.who.int/gb/ebwha/pdf_files/wha63/ a63_18-en.pdfmendations. Available at http://www.who.int/immunization/sage/Guidelines_development_recommendations. pdf; accessed January 2017.
Strebel PM et al. (2017). Chapter 21 - Measles vaccine. In: Offit SA, Plotkin WA, Orenstein PA (eds.).https://www.nejm.org/doi/pdf/10.1056/NEJMcp1905181
Vaccines (7th Edition). [In press] 4 See No. 45, 2016, pp. 525–536. 5
Rota PA et al. Measles. Nat Rev Dis Primers. 2016 Jul 14;2:16049. (NOT OA)
Global eradication of measles: report by the Secretariat. World Health Organization, Geneva, 2010. Available at http://apps.who.int/gb/ebwha/pdf_files/wha63/ a63_18-en.pdf; accessed January 2017.
7 Global Vaccine Action Plan 2011-2020. World Health Organization, Geneva, 2013. Available at http://www.who.int/immunization/global_vaccine_action_plan/ GVAP_doc_2011_2020/en/, accessed December 2016.
8 Pan American Health Organization. Plan of Action for Maintaining Measles, Rubella, and Congenital Rubella Syndrome Elimination in the Region of the Americas: Final Report [Internet]. 55th Direction Council; 66th session of the WHO Regional Committee for the Americas; 26-30 September 2016; Washington, DC. Washington, DC: PAHO; 2012 (Resolution CD55/INF/10). Available at http://www.paho.org/hq/index. php?option=com_content&view=article&id=12528%3Aregion-americas-declared-free-measles, accessed December 2016.
9 Thompson, KM. Evolution and use of dynamic transmission models for measles and rubella risk and policy analysis. Risk Analysis 2016; 36(7):1383–1403. 10 De Serres G, Gay NJ, Farrington CP. Epidemiology of transmissible diseases after elimination. Am J Epidemiol 2000; 151: 1039–1048. (NOT OA)
De Serres G, Gay NJ, Farrington CP. Epidemiology of transmissible diseases after elimination. Am J Epidemiol 2000; 151: 1039–1048 (NOT OA)
Module 7: measles update 2009. The Immunological basis for immunization series. World Health Organization, Geneva, 2009. Available at http://www.who.int/immunization/documents/ISBN9789241597555/en/index.html, accessed January 2017.
12 de Swart RL et al. Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. Journal of Virology. 2005; 79:11547–11551. https://doi.org/10.1128/jvi.79.17.11547-11551.2005
14 Fitzgerald TL et al. Measles with a possible 23 day incubation period. Communicable Diseases Intelligence. 2012; 36: 277–280. (NOT OA)
15 Griffin, D E. in Fields Virology (eds Fields, B. N.Howley, P. M.Cohen, J. I. & Knipe, D. M.) pp. 1042–1069 (Wolters Kluver/Lippincott Williams & Wilkins, 2013).
16 Robbins FC. Measles: clinical features. Pathogenesis, pathology and complications. Am J Dis Child. 1962 Mar;103:266–273. (NOT OA)
Perry RT and Halsey NA. The Clinical Significance of Measles: A Review. J Infect Dis. 2004 May 1;189(Supplement 1):S4–16. (NOT OA)
18 Campbell H et al. Review of the effect of measles vaccination on the epidemiology of SSPE. International Journal of Epidemiology. 2007;36:1334–1348. (NOT OA)
19 Wolfson LJ et al. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int. J. Epidemiol. 2009;38, 192–205. (NOT OA)
20 Palumbo P et al. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1992 Dec;11(12):1008–1014.
Treating measles in children. World Health Organization, Geneva, 1996. Available at http://apps.who.int/iris/handle/10665/63706, accessed December 2016.
22 Garly ML et al. Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau. BMJ. 2006 December 16;333(7581):1245. https://www.bmj.com/content/bmj/333/7581/1245.full.pdf
23 Vitamin A supplementation in infants and children 6–59 months of age. Available at http://www.who.int/elena/titles/guidance_summaries/vitamina_children/en/, accessed February 2017.
McLean HQ et al. Centers for Disease Control and Prevention. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisor Committee on Immunization Practices (ACIP). MMWR. 2013 Jun 14;62(RR-04): 1–34. https://www.cdc.gov/MMWr/preview/mmwrhtml/rr6204a1.htm
Knudsen KM et al. Child mortality following standard, medium or high titre measles immunization in West Africa. Int J Epidemiol. 1996 Jun;25(3):665–673. (NOT OA)
26 Parks CL et al. Comparison of predicted amino acid sequences of MV strains in the Edmonston vaccine lineage. Journal of Virology. 2001;75:910–920. doi: 10.1128/JVI.75.2.910-920.2001
27 Requirements for measles, mumps and rubella vaccines and combined vaccine (live). WHO Technical Report Series, No. 840 (Annex 3), World Health Organization, Geneva, 1994. Available at http://www.who.int/biologicals/publications/trs/areas/ vaccines/mmr/WHO_TRS_840_A3.pdf?ua=1, accessed December 2016.
Mina MJ et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015 May 8;348(6235):694–699. (NOT OA)
29 Stowe J et al. No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccine. Vaccine.2009;27:1422–1425. (NOT OA)
30 See No. 21, 2014, pp. 221–236. 31 Caceres VM et al. Factors determining prevalence of maternal antibody to MV throughout infancy: a review. Clinical Infectious Diseases. 2000, . (NOT OA)
33 Grading of scientific evidence – table I: Effectiveness of measles vaccine in young children and adolescents. Available at http://www.who.int/immunization/documents/measles_grad_effectiveness.pdf?ua=1
Grading of scientific evidence – table II: Safety and immunogenicity in HIV infected children. at http://www.who.int/immunization/measles_grad_HIV. pdf?ua=1
35 Report to SAGE on Evidence Supporting Measles Revaccination for HIV infected Children Receiving Highly Active Antiretroviral Therapy. Available at http://www. who.int/immunization/sage/meetings/2015/october/7_Measles_Revaccination_ HIV_Infected_Children_Report_SAGE_26_September_2015.pdf?ua=1, accessed January 2017. https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/measles/measles-evidence-recommendation-hiv.pdf?sfvrsn=50b14aa2_2
36 Davidkin I et al. Persistence of measles, mumps, and rubella antibodies in an MMRvaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197: 950–956.https://doi.org/10.1086/528993
37 Dine MS et al. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. J Infect Dis. 2004 May 1;189 Suppl 1:S123–130. https://doi.org/10.1086/380308
38 Paunio M et al. IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy. Expert Opinion on Pharmacotherapy. 2003;4:1215–1225. https://doi.org/10.1517/14656566.4.8.1215
39 Pannuti CS et al. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clinical and Diagnostic Laboratory Immunology. 2004;11:119–122. https://doi.org/10.1128/CDLI.11.1.119-122.2004
40 Grading of scientific evidence – table III: Duration of protection following measles immunization. Available at http://www.who.int/immunization/measles_grad_duration.pdf?ua=1
Information sheet. Observed rate of vaccine reactions – measles, mumps and rubella vaccines, May 2014. World Health Organization, Geneva, 2014. Available at http://www.who.int/vaccine_safety/initiative/tools/MMR_vaccine_rates_information_sheet.pdf?ua=1, accessed December 2016
. 42 Grading of scientific evidence – table IV: Safety of measles vaccine in young children and adolescents. Available at http://www.who.int/immunization/documents/ measles_grad_safety.pdf?ua=1
What clinicians need to know about MMRV vaccine safety. Atlanta, US Centers for Disease Control and Prevention. http://www.cdc.gov/vaccinesafety/vsd/mmrv.htm, accessed April 2017.
44 Schink T et al. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine. 2014 Feb 3;32(6):645–650. https://doi.org/10.1016/j.vaccine.2013.12.011
45 Angel JB et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann. Intern. Med. 1998;129:104-106. https://doi.org/10.7326/0003-4819-129-2-199807150-00007
46 Scott P et al. Measles Vaccination in HIV-Infected Children: Systematic Review and Meta-Analysis of Safety and Immunogenicity. Oxford Journals Medicine & Health The Journal of Infectious Diseases. Volume 204, Issue suppl 1.pp. S164-S178. https://doi.org/10.1093/infdis/jir071
The heterogeneity I2 value is defined as the proportion of the total variation in estimated risk ratios due to between-trial heterogeneity rather than to chance.
49 Grading of scientific evidence – table V: Measles revaccination of HIV-infected children receiving highly active antiretroviral therapy. Available at http://www.who.int/immunization/policy/position_papers/measles_grad_hiv_revac.pdf
51 Sukumaran L et al. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS). 20032013. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2015 May 15;60(10):e58. https://doi.org/10.1093/cid/civ061
52 Gao J et al. Epidemic of measles following the nationwide mass immunization campaign. BMC Infectious Diseases. 2013; 13: 139. http://www.biomedcentral.com/1471-2334/13/139
Zepp F et al. Immunogenicity and safety of a tetravalent measles-mumps-rubellavaricella vaccine co-administered with a booster dose of a combined diphtheriatetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12–23 months. European Journal of Pediatrics. 2007;166:857–864. https://link.springer.com/article/10.1007/s00431-007-0506-z
54 Vesikari T et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine co-administered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J. 2010 Jun;29(6):e47–56. (NOT OA)
55 Huang L-M et al. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan. Vaccine. 2014 Sep 15;32(41):5363–5369. https://doi.org/10.1016/j.vaccine.2014.02.085
56 Nascimento Silva JR et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011 Aug 26;29(37):6327–6334. https://doi.org/10.1016/j.vaccine.2011.05.019
57 Thompson KM and Odahowski CL (2016). Systematic review of health economic analyses of measles and rubella immunization interventions. Risk Analysis, 36(7), 1297–1314. https://doi.org/10.1111/risa.12331
58 Acharya A et al. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis. Vaccine. 2002 Sep 10;20:3332–3341. https://doi.org/10.1016/S0264-410X(02)00296-7
59 Pelletier L et al. A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine. 1998;16:989–996. https://doi.org/10.1016/S0264-410X(97)00281-8
60 Zhou F et al. An economic analysis of the current universal 2-dose measles-mumpsrubella vaccination program in the United States. International Journal of Infectious Diseases. 2004;189 Suppl 1:S131–145. https://doi.org/10.1086/378987
Dayan GH et al. Cost-effectiveness of three different vaccination strategies against measles in Zambian children. Vaccine. 2004;22:475–484. https://doi.org/10.1016/j.vaccine.2003.07.007
62 Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva, World Health Organization, 2001. Available at http:// whqlibdoc.who.int/publications/2001/924154550x.pdf, accessed January 2017. (NOT OA)
63 Edejer TT et al. Cost effectiveness analysis of strategies for child health in developing countries. BMJ. 2005;331:1177. doi: https://doi.org/10.1136/bmj.38652.550278.
64 Fiedler JL et al. The cost of Child Health Days: a case study of Ethiopia’s Enhanced Outreach Strategy (EOS). Health Policy and Planning. 2008;23:222–233. https://doi.org/10.1093/heapol/czn015
65 Thompson KM and Odahowski CL. The costs and valuation of health impacts of measles and rubella risk management policies. Risk Anal. 2016 Jul;36(7):13571382. (NOT OA)
66 Ozawa S et al. Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20. Health Aff (Millwood). 2016 Feb;35(2):199207. (NOT OA)
67 Evidence-to-recommendation table for measles vaccine. Available at http://www. who.int/immunization/policy/position_papers/measles_evidence_recommendation.pdf, accessed April 2017. https://doi.org/10.1016/j.vaccine.2017.07.066
Planning and Implementing High-Quality Supplementary Immunization Activities for Injectable Vaccines Using an Example of Measles and Rubella Vaccines. Field Guide. Available at http://www.who.int/immunization/diseases/measles/SIA-FieldGuide.pdf?ua=1, accessed January 2017. (NOT OA)
Evidence-to-recommendation table for revaccination of HIV infected. Available http://www.who.int/immunization/policy/position_papers/measles_evidence_recommendation_hiv.pdf; accessed April 2017. https://doi.org/10.1016/j.vaccine.2017.07.066
